Eben Tessari Sells 17,500 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at $3,226,805.01. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Kiniksa Pharmaceuticals Stock Performance

KNSA opened at $26.74 on Friday. The stock’s fifty day moving average is $23.45 and its 200-day moving average is $20.72. Kiniksa Pharmaceuticals, Ltd. has a one year low of $14.12 and a one year high of $27.92. The company has a market capitalization of $1.90 billion, a PE ratio of 243.09 and a beta of 0.38.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. The company had revenue of $108.30 million during the quarter, compared to the consensus estimate of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. Kiniksa Pharmaceuticals’s revenue was up 51.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.02) EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.05 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on KNSA shares. Wedbush increased their price target on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Wells Fargo & Company initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, May 3rd. They set an “overweight” rating and a $34.00 target price on the stock. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $32.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the 1st quarter valued at $71,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the second quarter worth $100,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 88.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after purchasing an additional 3,611 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at $177,000. Finally, Arizona State Retirement System purchased a new position in Kiniksa Pharmaceuticals in the 2nd quarter worth about $209,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.